Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

pro.med.cs praha a.s. array - 9568 betaxolol-hydrochlorid - tableta - 20mg - betaxolol

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

teva pharmaceuticals cr, s.r.o., praha array - 9568 betaxolol-hydrochlorid - potahovaná tableta - 20mg - betaxolol

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

dr. gerhard mann, chem.- pharm. fabrik gmbh, berlín array - 11773 karteolol-hydrochlorid - oční kapky, roztok s prodlouženým uvolňováním - 20mg/ml - karteolol

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

vitabalans oy, hämeenlinna array - 4998 celiprolol-hydrochlorid - potahovaná tableta - 200mg - celiprolol

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

cheplapharm arzneimittel gmbh, greifswald array - 4237 acebutolol-hydrochlorid - potahovaná tableta - 400mg - acebutolol

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

cheplapharm arzneimittel gmbh, greifswald array - 4998 celiprolol-hydrochlorid - potahovaná tableta - 200mg - celiprolol

Europska Unija - češki - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Europska Unija - češki - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomid - roztroušená skleróza - selektivní imunosupresiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Europska Unija - češki - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridin - roztroušená skleróza - další léky na nervový systém - přípravek fampyra je indikován pro zlepšení chůze u dospělých pacientů s roztroušenou sklerózou s pohybovými postižení (il2ra 4-7).

Europska Unija - češki - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - roztroušená skleróza - selektivní imunosupresiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.